|
1
|
Interpreting the significance of changes in health-related quality-of-life scores.
|
J Clin Oncol
|
1998
|
9.89
|
|
2
|
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases.
|
Pain
|
1983
|
6.46
|
|
3
|
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
|
J Natl Cancer Inst
|
2005
|
5.92
|
|
4
|
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.
|
Lancet
|
2000
|
4.43
|
|
5
|
Life after breast cancer: understanding women's health-related quality of life and sexual functioning.
|
J Clin Oncol
|
1998
|
4.35
|
|
6
|
Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.
|
Qual Life Res
|
1998
|
3.71
|
|
7
|
The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.
|
J Clin Oncol
|
1996
|
3.68
|
|
8
|
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
|
J Clin Oncol
|
1996
|
3.22
|
|
9
|
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
|
J Natl Cancer Inst
|
2003
|
3.16
|
|
10
|
Methodologic lessons learned from hot flash studies.
|
J Clin Oncol
|
2001
|
2.82
|
|
11
|
Breast cancer in younger women: reproductive and late health effects of treatment.
|
J Clin Oncol
|
2003
|
2.64
|
|
12
|
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
|
J Clin Oncol
|
2002
|
2.61
|
|
13
|
Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.
|
Breast Cancer Res Treat
|
2005
|
2.57
|
|
14
|
Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial.
|
Obstet Gynecol
|
2006
|
2.57
|
|
15
|
MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors.
|
Comput Methods Programs Biomed
|
1996
|
2.55
|
|
16
|
The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer.
|
J Pain Symptom Manage
|
2001
|
2.44
|
|
17
|
Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.
|
Lancet
|
2005
|
2.39
|
|
18
|
Quality of life among younger women with breast cancer.
|
J Clin Oncol
|
2005
|
2.19
|
|
19
|
Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement.
|
J Clin Epidemiol
|
1997
|
1.72
|
|
20
|
Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5.
|
J Clin Oncol
|
2006
|
1.68
|
|
21
|
Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life.
|
Cancer
|
1998
|
1.65
|
|
22
|
Correlates of use of different types of complementary and alternative medicine by breast cancer survivors in the nurses' health study.
|
Breast Cancer Res Treat
|
2006
|
1.57
|
|
23
|
The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.
|
Ann Oncol
|
1990
|
1.56
|
|
24
|
Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.
|
Oncologist
|
2007
|
1.54
|
|
25
|
Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy.
|
J Clin Oncol
|
1995
|
1.43
|
|
26
|
Application of random-effects regression models in relapse research.
|
Addiction
|
1996
|
1.07
|
|
27
|
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications.
|
Breast Cancer Res Treat
|
1997
|
1.05
|
|
28
|
Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors.
|
Psychooncology
|
2007
|
0.98
|
|
29
|
Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer.
|
Breast Cancer Res Treat
|
2004
|
0.97
|
|
30
|
Breast cancer in younger women: effects on interpersonal and family relations.
|
J Natl Cancer Inst Monogr
|
1994
|
0.95
|
|
31
|
Mind control of menopause.
|
Womens Health Issues
|
2003
|
0.83
|
|
32
|
Can hypnosis reduce hot flashes in breast cancer survivors? A literature review.
|
Am J Clin Hypn
|
2004
|
0.83
|
|
33
|
Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study.
|
BMJ Open
|
2013
|
0.79
|